From: German guidelines on community-acquired acute bacterial meningitis in adults
Pathogen | Antibiotics1 |
---|---|
Neisseria meningitidis 2 | |
- ceftriaxone/cefotaxim-susceptible (MIC ≤ 0,125 mg/l) | ceftriaxone3 |
- ceftriaxone/cefotaxim-resistant (MIC > 0,125 mg/l) | meropenem |
Streptococcus pneumoniae | |
- ceftriaxone/cefotaxim-susceptible (MIC ≤ 0,5 mg/l) | ceftriaxone3 |
meropenem | |
- ceftriaxone/cefotaxim-resistant (MIC > 0,5 mg/l) | ceftriaxone3 + vancomycin, |
ceftriaxone3 + rifampicin4, | |
Meropenem | |
Haemophilus influenzae | ceftriaxone3, |
ampicillin | |
Groupp-B-streptococci (Streptococcus agalactiae) | penicillin G, |
ceftriaxone, | |
ampicillin, | |
vancomycin | |
Gram-negative enterobacterales (e.g. Klebsiella spp., E. coli, Proteus spp.) | ceftriaxone3, |
meropenem, | |
cefepime | |
Pseudomonas aeruginosa | ceftazidime, |
meropenem, | |
cefepime | |
(combination with fosfomycin4can be considered) | |
Staphylococci | |
- methicillin-susceptible | cefazolin, |
flucloxacillin | |
(combination with fosfomycin4 or | |
rifampicin4 can be considered) | |
vancomycin, | |
- Methicillin-resistant | linezolid5 |
(combination with fosfomycin4 or | |
rifampicin4 can be considered) | |
Listeria monocytogenes | ampicillin, |
trimethoprim-sulfamethoxazol, | |
meropenem | |
(combination with fosfomycin4 or | |
rifampicin4 can be considered) |